🔗 Visit the ClinicalTrials.gov page for NCT01767792
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Advances in the treatment of neurofibromatosis-associated tumours. | Nat Rev Clin Oncol | 2013 | 1.26 |
| 2 | Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. | Oncoimmunology | 2014 | 1.05 |
| 3 | Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. | Neuro Oncol | 2016 | 0.91 |
| 4 | Neurofibromatosis-related tumors: emerging biology and therapies. | Curr Opin Pediatr | 2015 | 0.85 |
| 5 | Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. | J Clin Oncol | 2016 | 0.81 |
| 6 | Advances in paediatric cancer treatment. | Transl Pediatr | 2014 | 0.76 |
| 7 | Chemoprevention for neurofibromatosis 2: just over the horizon? | Neuro Oncol | 2014 | 0.75 |